Lipodystrophy Clinical Trial
Official title:
Open, Non-comparative, Multicentre Clinical Investigation to Evaluate the Performance and Safety of the Medical Device Plenhyage® (Polymerised Polynucleotides Dermal Filler) in the Treatment of Dermal Tissue Defects
The Research Question of the present study is the following: in a population of men and women presenting dermal tissue defects (scars, atrophic scars, depressed plaques, and lipodystrophy defects) will Plenhyage® significantly improve the appearance of treated areas, results observed after 4, 8 and 12 weeks?
Plenhyage® is a different type of dermal filler, an innovative course of polynucleotides to restore skin damage. The polynucleotide chain attracts water molecules, protecting against free radicals, acting as an absorber of hydroxyl radicals OH, which accumulate from stress, cell damage and UV rays. It also guarantees moisturising action and protection against free radicals. Nucleotides, natural fractions of DNA and RNA, are components of Plenhyage® with an antioxidant, protective effect. These characteristics allow Plenhyage® to be used as a temporary filler for subcutaneous areas to correct small defects in the dermal tissue due to lipodystrophies or the presence of fibrotic tissues as scars, caused by pathologies or trauma. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05419037 -
Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy
|
||
| Recruiting |
NCT03059121 -
The Cleveland Cardiometabolic Cohort
|
||
| Completed |
NCT00656175 -
Raltegravir Therapy for Women With HIV and Fat Accumulation
|
Phase 2 | |
| Completed |
NCT00202241 -
The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS
|
N/A | |
| Completed |
NCT00006185 -
Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome
|
Phase 1 | |
| Recruiting |
NCT02262832 -
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
|
Phase 3 | |
| Completed |
NCT01679197 -
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
|
Phase 2 | |
| Completed |
NCT02647853 -
Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers
|
Phase 1 | |
| Active, not recruiting |
NCT00715546 -
Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy
|
Phase 1 | |
| Completed |
NCT00069004 -
A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth
|
N/A | |
| Completed |
NCT00025883 -
Leptin to Treat Lipodystrophy
|
Phase 2 | |
| Completed |
NCT00001142 -
Metabolism and Body Shape of Healthy Children and Children With Chronic Infections
|
N/A | |
| Active, not recruiting |
NCT02262806 -
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
|
Phase 2 | |
| Completed |
NCT02258685 -
Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients.
|
||
| Completed |
NCT00192621 -
Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects
|
Phase 4 | |
| Completed |
NCT00006190 -
A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy
|
Phase 4 | |
| Recruiting |
NCT05930106 -
Carotid Doppler Peak Velocity Variation in Liposuction Fluid Management
|
N/A | |
| Completed |
NCT00004329 -
Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy
|
N/A | |
| Recruiting |
NCT04656054 -
Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance
|
||
| Completed |
NCT00082628 -
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
|
Phase 3 |